Rosetta Genomics microRNA-based Diagnostic Assays to be Showcased in an
Industry Expert Theater Presentation at ASCO's 2013 Annual Meeting
PHILADELPHIA and REHOVOT, Israel, May 7, 2013
PHILADELPHIA and REHOVOT, Israel, May 7, 2013 /PRNewswire/ --Rosetta Genomics
Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based
molecular diagnostics, today announces that the Company's miRview^® suite of
oncology diagnostic assays will be highlighted in an "Industry Expert Theater
Presentation" at the American Society of Clinical Oncologists (ASCO) 2013
Annual Meeting taking place from May 31-June 4 at McCormick Place Convention
Center in Chicago. The "Industry Expert Theater Presentation" is a series of
hour-long presentations from industry leaders sharing the latest in oncology
practices, products, services and technologies*. Kenneth A. Berlin, Rosetta
Genomics' President and Chief Executive Officer, and E. Robert Wassman, MD,
FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, will deliver a
presentation entitled, "Application of microRNAs in Oncology Diagnostics," on
Saturday, June 1^st at 3:00 p.m. in the Oncology Professionals Hall.
"We are delighted to have secured a session in this prestigious program. This
is an exceptional opportunity for us to showcase Rosetta's cutting edge,
microRNA-based oncology diagnostic assays before an audience of influential
oncologists who are seeking to learn about the latest products and
technologies that will assist them in optimizing treatment protocols for their
patients," said Mr. Berlin.
"Developments in targeted cancer therapies are driving the need for more
accurate classification of tumor types, which help to guide treatment
decisions. Our microRNA technologies, with their high reproducibility,
robustness, and accuracy are well suited to provide valuable clinical
information to predict and diagnose cancer, and therefore, help to optimize
treatment," added Dr. Wassman.
About miRview^® Testing Services
miRview^® assays are a series of microRNA-based diagnostic testing services
offered by Rosetta Genomics. The Rosetta Cancer Origin Test, miRview^® mets²,
accurately identifies the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). miRview^® meso
diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview^®
lung accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® assays are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² assay, 60,000 from miRview^® meso, 65,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000, Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.
*The Industry Expert Theater Presentation is not an official presentation of
the 2013 ASCO Annual Meeting. It is not sponsored or endorsed by ASCO or the
Conquer Cancer Foundation, nor is it CME-accredited.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta's development or commercialization of molecular diagnostics, the
market acceptance of Rosetta's miRview^®assays,particularly
miRview^®mets^2, Rosetta's capitalization of its microRNA platform, Rosetta's
patent positionand Rosetta's development of personalized medicine products
and servicesconstitute forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2012as filed with
the SEC. In addition, any forward-looking statements represent Rosetta's views
only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
Anne Marie Fields
SOURCE Rosetta Genomics, Ltd.
Press spacebar to pause and continue. Press esc to stop.